Conversion of Propranolol to Carvedilol Improves Renal Perfusion and Outcome in Patients With Cirrhosis and Ascites.
Journal
Journal of clinical gastroenterology
ISSN: 1539-2031
Titre abrégé: J Clin Gastroenterol
Pays: United States
ID NLM: 7910017
Informations de publication
Date de publication:
01 09 2021
01 09 2021
Historique:
received:
11
05
2020
accepted:
18
08
2020
pubmed:
30
9
2020
medline:
27
10
2021
entrez:
29
9
2020
Statut:
ppublish
Résumé
In recent years, concerns have been raised on the potential adverse effects of nonselective beta-blockers, and particularly carvedilol, on renal perfusion and survival in decompensated cirrhosis with ascites. We investigated the long-term impact of converting propranolol to carvedilol on systemic hemodynamics and renal function, and on the outcome of patients with stable cirrhosis and grade II/III nonrefractory ascites. Ninety-six patients treated with propranolol for esophageal varices' bleeding prophylaxis were prospectively evaluated. These patients were randomized in a 2:1 ratio to switch to carvedilol at 12.5 mg/d (CARVE group; n=64) or continue propranolol (PROPRA group; n=32). Systemic vascular resistance, vasoactive factors, glomerular filtration rate, and renal blood flow were evaluated at baseline before switching to carvedilol and after 6 and 12 months. Further decompensation and survival were evaluated at 2 years. During a 12-month follow-up, carvedilol induced an ongoing improvement of systemic vascular resistance (1372±34 vs. 1254±33 dynes/c/cm5; P=0.02) along with significant decreases in plasma renin activity (4.05±0.66 vs. 6.57±0.98 ng/mL/h; P=0.01) and serum noradrenaline (76.7±8.2 vs. 101.9±10.5 pg/mL; P=0.03) and significant improvement of glomerular filtration rate (87.3±2.7 vs. 78.7±2.3 mL/min; P=0.03) and renal blood flow (703±17 vs. 631±12 mL/min; P=0.03); no significant effects were noted in the PROPRA group. The 2-year occurrence of further decompensation was significantly lower in the CARVE group than in the PROPRA group (10.5% vs. 35.9%; P=0.003); survival at 2 years was significantly higher in the CARVE group (86% vs. 64.1%; P=0.01, respectively). Carvedilol at the dose of 12.5 mg/d should be the nonselective beta-blocker treatment of choice in patients with cirrhosis and nonrefractory ascites, as it improves renal perfusion and outcome.
Sections du résumé
BACKGROUND
In recent years, concerns have been raised on the potential adverse effects of nonselective beta-blockers, and particularly carvedilol, on renal perfusion and survival in decompensated cirrhosis with ascites. We investigated the long-term impact of converting propranolol to carvedilol on systemic hemodynamics and renal function, and on the outcome of patients with stable cirrhosis and grade II/III nonrefractory ascites.
PATIENTS AND METHODS
Ninety-six patients treated with propranolol for esophageal varices' bleeding prophylaxis were prospectively evaluated. These patients were randomized in a 2:1 ratio to switch to carvedilol at 12.5 mg/d (CARVE group; n=64) or continue propranolol (PROPRA group; n=32). Systemic vascular resistance, vasoactive factors, glomerular filtration rate, and renal blood flow were evaluated at baseline before switching to carvedilol and after 6 and 12 months. Further decompensation and survival were evaluated at 2 years.
RESULTS
During a 12-month follow-up, carvedilol induced an ongoing improvement of systemic vascular resistance (1372±34 vs. 1254±33 dynes/c/cm5; P=0.02) along with significant decreases in plasma renin activity (4.05±0.66 vs. 6.57±0.98 ng/mL/h; P=0.01) and serum noradrenaline (76.7±8.2 vs. 101.9±10.5 pg/mL; P=0.03) and significant improvement of glomerular filtration rate (87.3±2.7 vs. 78.7±2.3 mL/min; P=0.03) and renal blood flow (703±17 vs. 631±12 mL/min; P=0.03); no significant effects were noted in the PROPRA group. The 2-year occurrence of further decompensation was significantly lower in the CARVE group than in the PROPRA group (10.5% vs. 35.9%; P=0.003); survival at 2 years was significantly higher in the CARVE group (86% vs. 64.1%; P=0.01, respectively).
CONCLUSION
Carvedilol at the dose of 12.5 mg/d should be the nonselective beta-blocker treatment of choice in patients with cirrhosis and nonrefractory ascites, as it improves renal perfusion and outcome.
Identifiants
pubmed: 32991355
pii: 00004836-202109000-00014
doi: 10.1097/MCG.0000000000001431
doi:
Substances chimiques
Carvedilol
0K47UL67F2
Propranolol
9Y8NXQ24VQ
Types de publication
Journal Article
Randomized Controlled Trial
Langues
eng
Sous-ensembles de citation
IM
Pagination
721-729Informations de copyright
Copyright © 2020 Wolters Kluwer Health, Inc. All rights reserved.
Références
Garcia-Tsao G, Abraldes JG, Berzigotti A, et al. Portal hypertension bleeding in cirrhosis: risk stratification, diagnosis, and management: 2016 Practice guidance by the American Association for the Study of Liver Diseases. Hepatology. 2017;65:310–335.
Villanueva C, Albilos A, Genesca J, et al. β blockers to prevent decompensation of cirrhosis in patients with clinically significant portal hypertension (PREDESCI): a randomised, double-blind, placebo-controlled, multicenter trial. Lancet. 2019;393:1597–1608.
Reiberger T, Mandorfer M. Beta adrenergic blockade and decompensated cirrhosis. J Hepatol. 2017;66:849–859.
Afonso RA, Patarrao RS, Macedo MP, et al. Carvedilol action is dependent on endogenous production of nitric oxide. Am J Hypertens. 2006;19:419–425.
Ling L, Li G, Wang G, et al. Carvedilol improves liver cirrhosis in rats by inhibiting hepatic stellate cell activation, proliferation, invasion and collagen synthesis. Mol Med Rep. 2019;20:1605–1612.
Banares R, Moitinho E, Matilla A, et al. Randomized comparison of long-term carvedilol and propranolol administration in the treatment of portal hypertension in cirrhosis. Hepatology. 2002;36:1367–1373.
Reiberger T, Ulbrich G, Ferlitsch A, et al. Carvedilol for primary prophylaxis of variceal bleeding in cirrhotic patients with haemodynamic non-response to propranolol. Gut. 2013;62:1634–1641.
Moctezuma-Velazquez C, Kalainy S, Abraldes JG, et al. Beta-blockers in patients with advanced liver disease: has the dust settled? Liver Transpl. 2017;23:1058–1069.
Serste T, Melot C, Francoz C, et al. Deleterious effects of beta-blockers on survival in patients with cirrhosis and refractory ascites. Hepatology. 2015;52:1017–1022.
Kim SG, Larson JJ, Lee JS, et al. Beneficial and harmful effects of non-selective beta-blockade on acute kidney injury in liver transplant candidates. Liver Transpl. 2017;23:733–740.
Kalambokis GN, Baltayiannis G, Christou L, et al. Red signs and not severity of cirrhosis should determine non-selective β-blocker treatment in Child-Pugh C cirrhosis with small varices: increased risk of hepatorenal syndrome and death beyond 6 months of propranolol use. Gut. 2016;65:1228–1230.
Kalambokis GN, Christodoulou D, Baltayiannis G, et al. Propranolol use beyond 6 months increases mortality in patients with Child-Pugh C cirrhosis and ascites. Hepatology. 2016;64:1806–1808.
Llach J, Gines P, Arroyo V, et al. Prognostic value of arterial pressure, endogenous vasoactive systems, and renal function in cirrhotic patients admitted to the hospital for the treatment of ascites. Gastroenterology. 1988;94:482–487.
Krag A, Bendtsen F, Henriksen JH, et al. Low cardiac output predicts development of hepatorenal syndrome and survival in patients with cirrhosis and ascites. Gut. 2010;59:105–110.
Schwarzer R, Kivaranovic D, Paternostro R, et al. Carvedilol for reducing portal pressure in primary prophylaxis of variceal bleeding: a dose-response study. Aliment Pharmacol Ther. 2018;47:1162–1169.
Njei B, McCarty TR, Garcia-Tsao G. Beta-blockers in patients with cirrhosis and ascites: type of beta-blocker matters. Gut. 2016;65:1393–1394.
European Association for the Study of the Liver. EASL Clinical practice guidelines for the management of patients with decompensated cirrhosis. J Hepatol. 2018;69:406–460.
De BK, Das D, Sen S, et al. Acute and 7-day portal pressure response to carvedilol and propranolol in cirrhotics. J Gastroenterol Hepatol. 2002;17:183–189.
Holboth L, Moller S, Gronbaek H, et al. Carvedilol or propranolol in portal hypertension? A randomized comparison. Scand J Gastroenterol. 2012;47:467–474.
Holboth L, Bendtsen F, Hansen EF, et al. Effects of carvedilol and propranolol on circulatory regulation and oxygenation in cirrhosis: a randomized study. Dig Liver Dis. 2014;46:251–256.
Kim SG, Kim TY, Sohn JH, et al. A randomized, multi-center, open-label study to evaluate the efficacy of carvedilol vs. propranolol to reduce portal pressure in patients with liver cirrhosis. Am J Gastroenterol. 2016;111:1582–1590.
Li T, Ke W, Sun P, et al. Carvedilol for portal hypertension in cirrhosis: systematic review with meta-analysis. BMJ Open. 2016;6:e010902.
Frishman WH. Carvedilol. N Engl J Med. 1998;339:1759–1765.
Stanley AJ, Therapondos G, Helmy A, et al. Acute and chronic haemodynamic and renal effects of carvedilol in patients with cirrhosis. J Hepatol. 1999;30:479–484.
Moller S, Hobolth L, Winkler C, et al. Determinants of the hyperdynamic circulation and central hypovolaemia in cirrhosis. Gut. 2011;60:1254–1259.
Bakris GL, Hart P, Ritz E. Beta blockers in the management of chronic kidney disease. Kidney Int. 2006;70:1905–1913.
Kirnake V, Arora A, Gupta V, et al. Hemodynamic response to carvedilol is maintained for long periods and leads to better clinical outcome in cirrhosis: a prospective study. J Clin Exp Hepatol. 2016;6:175–185.
Leithead JA, Rajoriya N, Tehami N, et al. Non-selective β-blockers are associated with improved survival in patients with ascites listed for liver transplantation. Gut. 2015;64:1111–1119.
Sinha R, Lockman KA, Mallawaarachchi N, et al. Carvedilol use is associated with liver cirrhosis and ascites. J Hepatol. 2017;67:40–46.
Stanley AJ, Dickson S, Hayes PC, et al. Multicentre randomised controlled study comparing carvedilol with variceal band ligation in the prevention of variceal rebleeding. J Hepatol. 2014;61:1014–1019.